Emerging drugs for schizophrenia

Bibliography

• Cadet JL, Jayanthi S, McCoy MT. Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration. CNS Neurol Disord Drug Targets 2010;9(5):526-38
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS, Castner SA, Svensson TH, Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction [Review]. Psychopharmacology (Berl) 2004;174(1):3-16
   PubMed Web of Science ®Google Scholar
• Howes OD, Egerton A, Allan V, Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009;15(22):2550-9
   PubMed Web of Science ®Google Scholar
• Millan MJ, Buccafusco JJ, Loiseau F, The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol 2010;13(8):1035-51
   PubMed Web of Science ®Google Scholar
• Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71(4):533-54
   PubMed Web of Science ®Google Scholar
• Nocjar C, Roth BL, Pehek EA. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 2002;111(1):163-76
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Arvanitis L, Bauer D, Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004;161(6):975-84
   PubMed Web of Science ®Google Scholar
• Ichikawa J, Ishii H, Bonaccorso S, 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Neurochem 2001;76(5):1521-31
   PubMed Web of Science ®Google Scholar
• Invernizzi R, Pozzi L, Samanin R. Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU 6215, a 5-HT3 receptor antagonist. Neuropharmacology 1995;34(2):211-15
   PubMed Web of Science ®Google Scholar
• Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol 1989;40:191-225
   PubMed Web of Science ®Google Scholar
• Marcos B, Cabero M, Solas M, Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. Int J Neuropsychopharmacol 2010;13(6):775-84
   PubMed Web of Science ®Google Scholar
• Cifariello A, Pompili A, Gasbarri A. 5-HT(7) receptors in the modulation of cognitive processes [Review]. Behav Brain Res 2008;195(1):171-9
   PubMed Web of Science ®Google Scholar
• Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006;26(4-6):365-84
   PubMed Web of Science ®Google Scholar
• Marek GJ, Behl B, Bespalov AY. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? [Review]. Mol Pharmacol 2010;77(3):317-26
   PubMed Web of Science ®Google Scholar
• Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) 2005;179(1):154-63
   PubMed Web of Science ®Google Scholar
• Hu G, Duffy P, Swanson C, The regulation of dopamine transmission by metabotropic glutamate receptors. J Pharmacol Exp Ther 1999;289(1):412-16
   PubMed Web of Science ®Google Scholar
• Hu JL, Liu G, Li YC. Dopamine D1 receptor-mediated NMDA receptor insertion depends on Fyn but not Src kinase pathway in prefrontal cortical neurons. Mol Brain 2010;3:20
   PubMedGoogle Scholar
• Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9(11):984-97, 979
   PubMed Web of Science ®Google Scholar
• Grossberg GT. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. Curr Med Res Opin 2005;21(10):1631-9
   PubMed Web of Science ®Google Scholar
• Lester DB, Rogers TD, Blaha CD. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010;16(3):137-62
   PubMed Web of Science ®Google Scholar
• Bikadi Z, Simonyi M. Muscarinic and nicotinic cholinergic agonists: structural analogies and discrepancies. Curr Med Chem 2003;10(23):2611-20
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009;259(7):413-31
   PubMed Web of Science ®Google Scholar
• Lei G, Anastasio NC, Fu Y, Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-Methyl-D-aspertate receptor-mediated synaptic strength. J Neurochem 2009;109(4):1017-30
   PubMed Web of Science ®Google Scholar
• Ahlenius S. Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol 1999;84(5):193-6
   PubMedGoogle Scholar
• Schmidt ME, Janssens J, Kent J, Efficacy and Safey of JNJ-37822681, a fast dissociating D2 receptor antagonist, in the treatment of Schizophrenia. Poster, presented at the 23nd Congress of European College of Neuropsychopharmacology; Amsterdam, 9/2010
   Google Scholar
• Grunder G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs 2010;11(7):823-32
   PubMed Web of Science ®Google Scholar
• Bose A, Li D, Migliore R, The efficacy of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Poster, presented at the 23nd Congress of European College of Neuropsychopharmacology; Amsterdam, 9/2010
   Google Scholar
• Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25(6):904-14
   PubMed Web of Science ®Google Scholar
• Potkin SG, Litman RE, Torres R, Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28(2 Suppl 1):S4-11
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Cutler AJ, Polymeropoulos MH, Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(2 Suppl 1):S12-19
   PubMed Web of Science ®Google Scholar
• Kane JM, Lauriello J, Laska E, Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-35
   PubMed Web of Science ®Google Scholar
• Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist
   Google Scholar
• Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68(10):1492-500
   PubMed Web of Science ®Google Scholar
• Schoemaker J, Naber D, Vrijland P, Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010 2010;43(4):138-46
   Google Scholar
• Chapel S, Hutmacher MM, Haig G, Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009;49(11):1297-308
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Dritselis A, Yasothan U, Asenapine. Nat Rev Drug Discov 2009;8(11):843-4
   PubMed Web of Science ®Google Scholar
• Casey DE, Sands EE, Heisterberg J, Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 2008;200(3):317-31
   PubMed Web of Science ®Google Scholar
• Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 2010;70(10):1295-317
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 2009;52:S29-36
   PubMedGoogle Scholar
• Okugawa G, Kato M, Wakeno M, Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci 2009;63(3):322-8
   PubMed Web of Science ®Google Scholar
• Sumiyoshi T, Higuchi Y, Itoh T, Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta. Psychiatry Res 2009;172(3):180-3
   PubMed Web of Science ®Google Scholar
• Acadia Pharmaceuticals. ACADIA Pharmaceuticals announces results from ACP-104 IIb schizophrenia trial [online]. Available from: http://news.acadia-pharm.com [Accessed 7 September 2008]
   Google Scholar
• Garcia E, Robert M, Peris F, The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009;23(7):615-25
   PubMed Web of Science ®Google Scholar
• Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs 2010;24(1):65-84
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA Approves Latuda to Treat Schizophrenia in Adults. Press release, 28 October 2010. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm
   Google Scholar
• Ishibashi T, Horisawa T, Tokuda K, Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334(1):171-81
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogasa M, Guarino J, Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(6):829-36
   PubMed Web of Science ®Google Scholar
• Nudelman A, Gil-Ad I, Shpaisman N, A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. J Med Chem 2008;51(9):2858-62
   PubMed Web of Science ®Google Scholar
• Geffen Y, Nudelman A, Gil-Ad I, BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. Eur Neuropsychopharmacol 2009;19(1):1-13
   PubMed Web of Science ®Google Scholar
• Appel L, Geffen Y, Heurling K, BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans. Neuropsychopharmacol 2009;19(12):841-50
   Web of Science ®Google Scholar
• Leone M, Grazzi L, La Mantia L, Flunarizine in migraine: a minireview. 1991;31(6):388-91
   Google Scholar
• Schmidt R, Oestreich W. Flunarizine in the treatment of vestibular vertigo: experimental and clinical data. J Cardiovasc Pharmacol 1991;18(Suppl 8):S27-30
   PubMed Web of Science ®Google Scholar
• Agnoli A, Manna V, Martucci N, Randomized double-blind study of flunarizine versus placebo in patients with chronic cerebrovascular disorders. Int J Clin Pharmacol Res 1988;8(3):189-97
   PubMedGoogle Scholar
• Bisol LW, Brunstein MG, Ottoni GL, Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. J Clin Psychiatry 2008;69(10):1572-9
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Mohammadi N, Noroozian M, Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res 2009;107(2-3):206-12
   PubMed Web of Science ®Google Scholar
• Chaves C, Marque CR, Trzesniak C, Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz J Med Biol Res 2009;42(11):1002-14
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Javitt DC, Marder SR, The cognitive and negative symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164(10):1593-602
   PubMed Web of Science ®Google Scholar
• Goff DC, Cather C, Gottlieb JD, Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008;106(2-3):320-7
   PubMed Web of Science ®Google Scholar
• Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008;258(1):16-27
   PubMed Web of Science ®Google Scholar
• Lane HY, Liu YC, Huang CL, Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008;63(1):9-12
   PubMed Web of Science ®Google Scholar
• Lane HY, Lin CH, Huang YJ, A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010;13(4):451-60
   PubMed Web of Science ®Google Scholar
• Pinard E, Alanine A, Alberti D, Selective GlyT1 Inhibitors: discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem 2010;53:4603-14
   PubMed Web of Science ®Google Scholar
• Roche: Investor Update. Basel 10. November 2009
   Google Scholar
• de Lucena D, Fernandes BS, Berk M, Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009;70(10):1416-23
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Papadakis K, Csernansky J, A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009;34(5):1322-9
   Google Scholar
• Marenco S, Egan MF, Goldberg TE, Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res 2002;57(2-3):221-6
   PubMed Web of Science ®Google Scholar
• Goff DC, Lamberti JS, Leon AC, A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008;33(3):465-72
   PubMed Web of Science ®Google Scholar
• Patil ST, Zhang L, Martenyi F, Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-7
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Zhang L, Williams JE. LY2140023 monohydrate: an agonist at the mGlu2/3 receptor for the treatment of schizophrenia. Schizophrenia International Research Society(SIRS) International Scientific Conference [Poster]; 10 – 14 April 2010; Florence, Italy
   Google Scholar
• Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl). 2004;174(1):54-64
   PubMed Web of Science ®Google Scholar
• Kitagawa H, Takenouchi T, Azuma R, Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003;28(3):542-51
   PubMed Web of Science ®Google Scholar
• Olincy A, Harris JG, Johnson LL, Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63(6):630-8
   PubMed Web of Science ®Google Scholar
• Freedman R, Olincy A, Buchanan RW, Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008;165(8):1040-7
   PubMed Web of Science ®Google Scholar
• Astra Zeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia. 2008
   Google Scholar
• Smith RC, Lindenmayer JP, Davis JM, Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009;110(1-3):149-55
   PubMed Web of Science ®Google Scholar
• Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006;70(3):801-5. [Epub 9 Jun 2006]
   PubMed Web of Science ®Google Scholar
• Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007;164(8):1269-70
   PubMed Web of Science ®Google Scholar
• Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164(8):1269
   PubMed Web of Science ®Google Scholar
• Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006;60(6):530-3
   PubMed Web of Science ®Google Scholar
• Lee SW, Lee JG, Lee BJ, A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 2007;22(2):63-8
   PubMed Web of Science ®Google Scholar
• Dyer MA, Freudenreich O, Culhane MA, High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 2008;102(1-3):88-95
   PubMed Web of Science ®Google Scholar
• Conley RR, Boggs DL, Kelly DL, The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol 2009;32(2):69-74
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res 2011;125(2-3):267-77
   Google Scholar
• Shekhar A, Potter WZ, Lightfoot J, Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008;165(8):1033-9
   PubMed Web of Science ®Google Scholar
• Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry 2010;11(2 Pt 2):208-19
   PubMed Web of Science ®Google Scholar
• Hallak JE, Machado-de-Sousa JP, Crippa JA, Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr 2010;32(1):56-61
   PubMed Web of Science ®Google Scholar
• Kelly LD, Gorelick AD, McMahon PR, Effects of cannabinoid-1Receptor antagonist rimonabant on psychiatricsymptoms in overweight people with schizophrenia: a randomized, double-blind pilot study. ACNP Annual Meeting [Poster]; 6 – 10 December 2009; Hollywood, Florida
   Google Scholar
• Ross MB, Seguin J, Sieswerda EL. Omega-3 fatty acids as treatments for illness: which disorder and fatty acid? Lipids Health Dis 2007;6:21
   PubMed Web of Science ®Google Scholar
• Amminger GP, Schafer MR, Papageorgiou K, Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67(2):146-54
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hinze-Selch D, Stawicki S, Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007;12(2):206-20
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Tabatabaee M, Amini H, Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007;90(1-3):179-85
   PubMed Web of Science ®Google Scholar
• Muller N, Krause D, Dehning S, Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010;121(1-3):118-24
   Google Scholar
• Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol 2010;13(2):257-71
   PubMed Web of Science ®Google Scholar